US2015184198A1PendingUtilityA1

Compositions, methods and uses for poxvirus elements in vaccine constructs

47
Assignee: TAKEDA VACCINES INCPriority: Nov 20, 2009Filed: Mar 11, 2015Published: Jul 2, 2015
Est. expiryNov 20, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Inventors:Dan T. StinchcombJorge E. OsorioTimothy D. PowellJeremy N. Jones
C12N 2760/16122C12N 2710/24143A61P 37/04A61P 31/16C07K 14/005A61K 2039/5256C12N 2760/16134C07K 2319/02C12N 2760/16034C12N 15/86A61K 39/145A61K 39/12A61P 31/20C12N 15/863C12N 2710/24134A61K 39/00
47
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Embodiments of the present invention generally disclose methods, compositions and uses for generating and expressing poxvirus constructs. In some embodiments, constructs may contain an influenza virus gene segment. In certain embodiments, methods generally relate to making and using compositions of constructs including, but not limited to, poxvirus vaccine compositions. In other embodiments, vaccine compositions are reported of use in a subject.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A composition for administration to a subject comprising:
 one or more constructs, comprising:   at least one poxvirus secretory signal sequence associated with at least one non-poxvirus peptide, wherein the one or more peptides are capable of producing an immune response in a subject.   
     
     
         2 . The composition of  claim 1 , wherein the non-poxvirus peptide is derived from bacteria, virus, mammals, fungi, protozoan, non-pathogenic organisms or a combination thereof. 
     
     
         3 . The composition of  claim 1 , wherein the non-poxvirus peptide comprises a virus and the viral non-poxvirus peptide comprises an influenza gene segment. 
     
     
         4 . The composition of  claim 3 , wherein the influenza gene segment comprises hemagglutinin (HA), neuraminidase (N), nucleoprotein (NP), matrix (M) polymerase (P) or fragment thereof or a combination thereof. 
     
     
         5 . The composition of  claim 3 , wherein the fragment comprises at least 6, or at least 8, or at least 10 contiguous amino acids of an influenza gene segment. 
     
     
         6 . The composition of  claim 1 , wherein the poxvirus secretory signal sequence comprises, C13, B8R or any other poxvirus secretory signal sequence. 
     
     
         7 . The composition of  claim 1 , wherein the construct further comprises modified vaccinia. 
     
     
         8 . The composition of  claim 1 , further comprising one or more translational control sequences. 
     
     
         9 . The composition of  claim 1 , wherein the poxvirus comprises attenuated or modified poxvirus. 
     
     
         10 . A method for making a vaccine composition for administration to a subject comprising:
 obtaining one or more constructs of poxvirus; and   introducing at least one poxvirus secretory signal sequence associated with at least one non-poxvirus peptide to the construct,   
       wherein the vaccine composition is capable of inducing an immune response in the subject. 
     
     
         11 . The method of  claim 10 , wherein the non-poxvirus peptide is derived from bacteria, virus, mammals, fungi, protozoan, non-pathogenic organisms or a combination thereof. 
     
     
         12 . The method of  claim 10 , wherein at least one of the non-poxvirus peptide comprises an influenza gene segment. 
     
     
         13 . The method of  claim 10 , wherein the influenza gene segment comprises hemagglutinin (HA), neuraminidase (N), nucleoprotein (NP), matrix (M) or a combination thereof. 
     
     
         14 . A method for inducing an immune response in a subject comprising:
 administering a composition to the subject, the composition comprising:   at least one poxvirus secretory signal sequence and at least one non-poxvirus peptide, wherein the composition is capable of inducing an immune response in the subject.   
     
     
         15 . The method of  claim 14 , wherein the pox virus comprises vaccinia virus. 
     
     
         16 . The method of  claim 14 , wherein the vaccinia virus comprises modified vaccinia Ankara (MVA). 
     
     
         17 . A method for inducing an immune response in a subject comprising:
 administering a first composition to the subject, the composition comprising:   one or more poxvirus constructs, and   administering a second composition to the subject, the composition comprising:   one or more poxvirus constructs, comprising, at least one poxvirus secretory signal sequence and at least one non-poxvirus peptide,   
       wherein the composition is capable of inducing an immune response in the subject. 
     
     
         18 . The method of  claim 17 , wherein the poxvirus in the first composition comprises vaccinia virus. 
     
     
         19 . The method of  claim 18 , wherein the vaccinia virus comprises modified vaccinia Ankara (MVA). 
     
     
         20 . The method of  claim 17 , wherein the non-poxvirus peptide is derived from bacteria, virus, mammals, fungi, protozoan, non-pathogenic organisms or a combination thereof. 
     
     
         21 . The method of  claim 17 , wherein the first composition is administered to the subject between 6 months and immediately prior to the second composition. 
     
     
         22 . A method for inducing an immune response in a subject having prior exposure to poxvirus comprising:
 administering a composition to the subject, the composition comprising:   one or more poxvirus constructs comprising a poxvirus and at least one poxvirus secretory signal associated with at least one non-poxvirus peptide, wherein the vaccinia virus comprises modified vaccinia Ankara (MVA),   
       wherein the composition is capable of inducing an immune response in the subject having prior exposure to poxvirus. 
     
     
         23 . The method of  claim 22 , further comprising administering a boost of the composition between 6 months and immediately prior to a second administration of the composition. 
     
     
         24 . The method of  claim 22 , wherein administration of the composition comprises intradermal administration. 
     
     
         25 . A vaccine kit comprising;
 at least one poxvirus vaccine composition wherein the vaccine composition(s) comprises a poxvirus construct having at least one poxvirus secretory signal sequence and at least one non-poxvirus peptides; and   at least one container.   
     
     
         26 . The kit of  claim 25 , wherein at least one of the non-poxvirus peptides comprises one or more influenza virus gene segment(s). 
     
     
         27 . A composition for administration to a subject comprising:
 one or more constructs, comprising:   one or more poxviruses; and   at least one poxvirus secretory signal sequence associated with at least one non-poxvirus peptide,   
       wherein the one or more peptides are capable of producing an immune response in a subject.

Join the waitlist — get patent alerts

Track US2015184198A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.